#United States #New York #EyePoint Pharmaceuticals #DURAVYU #EYPT

Investigation Launched into EyePoint Pharmaceuticals

EyePoint Pharmaceuticals is currently under scrutiny as shares plummeted nearly 80% after the announcement regarding the Phase 3 LUCIA trial results for their drug, DURAVYU. This decline has prompted Levi & Korsinsky to initiate an investigation concerning potential violations of securities laws on behalf of investors who experienced financial losses.

Details of the Incident

On October 19, 2026, EyePoint Pharmaceuticals disclosed that DURAVYU did not achieve the primary endpoint in the Phase 3 LUCIA trial, which aimed to measure statistical non-inferiority in its efficacy compared to an established treatment, aflibercept. This information severely impacted investor confidence, resulting in a staggering decline in market value.

The LUCIA trial results showed that although DURAVYU met several secondary endpoints, including significantly lowering the treatment burden by 38%, it ultimately failed to meet its main goal. This discrepancy leaves investors feeling misled, raising concerns about the information they were provided prior to the stock's collapse.

Who is Affected?

Investors who held shares of EYPT during the time of the trial results may have legal standing. If you suffered financial losses due to the decline in stock value, you are encouraged to come forward. It is crucial to assess your potential eligibility for recovery as an affected party.

Joseph E. Levi, Esq., one of the leading attorneys at Levi & Korsinsky, highlighted the necessity for investors to document their losses, including brokerage records with purchase dates and quantities. This information will provide necessary evidence should legal action be pursued.

Legal Proceedings and Process

For those eligible to participate in the investigation, there are several straightforward steps to follow. First, gather relevant documentation reflecting your purchase of shares, the quantities held, and any sale transactions. Interested investors can submit their information for a complimentary assessment of their rights and potential recovery avenues. Importantly, there are no upfront costs associated with this review, as many legal matters of this nature are handled on a contingency basis.

This means that investors do not need to be concerned about incurring legal fees unless a recovery is achieved. Furthermore, it is stated that no court appearances or depositions are typically required from those involved in such investigations, allowing for a more stress-free process.

Next Steps for Investors

The directive for EyePoint Pharmaceuticals investors is clear: gather your documentation and consider participating in the investigation process. No immediate action is required to remain eligible, but the sooner you act, the better to safeguard your rights as a shareholder.

Investors who have already sold their EYPT shares at a loss can also seek compensation based on their historical purchase price. Although the stock's performance may make it seem bleak, there is recourse available for those affected by the unfavorable trial results.

As EyePoint Pharmaceuticals navigates this tumultuous period, the investigation serves as a potential lifeline for investors seeking to reclaim their losses. Awareness and prompt action could make all the difference in receiving the justice and compensation that is crucial after such significant financial upheaval.